Figure 4From: A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial Mean (± standard deviation) plasma lenalidomide (LEN) concentrations in the absence (Day 7) and presence (Day 8) of low-dose dexamethasone (LoDEX). Back to article page